The overall survival results were similar between the treatment arms for the overall cohort and for patients with PD-L1+ disease.
HLA-A*03 was associated with worse progression-free and overall survival.
There is no universal approach to patient selection for cytoreductive nephrectomy.
Half of urologists order routine urine cytology in patients with low-risk non-muscle-invasive bladder cancer.
Age, lymphovascular invasion, and histology predicted pathologic upstaging among patients with nonmuscle-invasive bladder cancer, a study found.
Patients with a pT0 tumor at the time of radical cystectomy are still at risk of recurrence and progression and should not be considered cured.
Researchers have questioned whether diabetes exerts adverse effects on the prognosis of RCC.
Neoadjuvant chemotherapy response rates differed among patients with genomically unstable bladder tumors, urothelial-like bladder tumors, and basal/squamous subtypes.
Belzutifan demonstrated activity against both RCC and non-RCC neoplasms associated with VHL disease.
Recent studies showed associations between quality of life scores and survival in lung and prostate cancer as well as renal cell carcinoma.
Serial radiation therapy could provide an alternative to standard-of-care systemic therapy.
Researchers hypothesized that adverse radiologic and pathologic T3 features are predictive of worse outcomes in small renal masses.
The median cancer-specific survival was 56.5 months.
The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months.
Patients with smaller target lesions at baseline were more likely to be long-term survivors.
The investigators aimed to understand how oncologists decide between IO/IO and IO/TKI treatment options via survey.
Nearly half of non-clear cell renal cell carcinoma samples were classified as proliferative.
The median time to first onset of key adverse reactions was within 5 months of starting lenvatinib-pembrolizumab.
Investigators presented the longest phase 3 follow-up reported for a checkpoint inhibitor combination therapy in aRCC.
Researchers determined that few patients with poor risk aRCC were receiving first-line avelumab plus axitinib.